United States First Circuit

ResetAA Font size: Print

Corbin v. Sarepta Therapeutics, Inc., 15-2135

Affirming the district court's decision that plaintiffs in a securities fraud class action suit had failed to allege facts creating a strong inference that the defendants intentionally or recklessly deceived the investing public when they expressed confidence that their product would be approved by the FDA when it ultimately wasn't, resulting in plummeting stock value.

Appellate Information

  • Argued
  • Submitted
  • Decided
  • Published 2017/08/22




  • United States First Circuit


FindLaw Career Center

    Select a Job Title

      Post a Job  |  View More Jobs

    View More